Featured Research

from universities, journals, and other organizations

How key controller protein is switched on revealed by research

Date:
July 10, 2014
Source:
Biochemical Society
Summary:
New research has uncovered how a complex protein pivotal in the development of cancer, viral infection and autoimmune diseases is activated. The discovery answers a key question about one of the most widely-researched proteins in human biology, which has been the subject of tens of thousands of research papers and millions in research funding.

New research has uncovered how a complex protein pivotal in the development of cancer, viral infection and autoimmune diseases is activated. The discovery answers a key question about one of the most widely-researched proteins in human biology, which has been the subject of tens of thousands of research papers and millions of pounds in research funding.

Jiazhen Zhang, a research student in Professor Sir Philip Cohen's laboratory at the University of Dundee, uncovered how the protein complex, called NF-κB, is activated. The results are published in the Biochemical Journal.

NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that controls transcription of DNA. NF-κB is found in almost all animal cell types and plays a key role in regulating the immune response to infection. Incorrect regulation of NF-κB has been linked to cancer, inflammatory, and autoimmune diseases, septic shock, viral infection, and improper immune development.

"NF-κB has been the subject of a vast amount of research for many years as it plays a critical role in inflammatory diseases and cancer," said Sir Philip. "It has been known for some time that the protein is activated by a kinase called IKKβ but there has been split opinion with regards to how the kinase itself is switched on.

"We have confirmed that another kinase, TAK1, is involved, but surprisingly it isn't sufficient to switch on IKKβ. Two other events need to happen in addition, namely the formation of an unusual type of ubiquitin chain and its attachment to IKKβ and then the addition of a second phosphate group on to IKKβ which remarkably is carried out by IKKβ itself. It is only then that IKKβ becomes competent to switch on NF-κB.

"This is complex biochemistry but working out the details of how proteins are switched on and off is how new ways to develop improved drugs to treat disease are identified. For example, the enzyme that makes the ubiquitin chains needed to activate IKKβ could now be targeted to develop a drug to treat inflammatory diseases."

The research was carried out in the Medical Research Council Protein Phosphorylation and Ubiquitylation Unit (MRC-PPU) at Dundee.

Peter Shepherd, Chair of the Biochemical Journal Editorial Board, said, "This signalling pathway is critical for a wide range of cellular responses, particularly stress responses. Understanding how this pathway is regulated is hugely important, and this paper finally clarifies one of the key steps in this process. This is important in not only understanding the disease process, but in the quest to develop new therapies that target this signalling pathway."


Story Source:

The above story is based on materials provided by Biochemical Society. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jiazhen Zhang, Kristopher Clark, Toby Lawrence, Mark W. Peggie, Philip Cohen. An unexpected twist to the activation of IKKβ: TAK1 primes IKKβ for activation by autophosphorylation. Biochemical Journal, 2014; 461 (3): 531 DOI: 10.1042/BJ20140444

Cite This Page:

Biochemical Society. "How key controller protein is switched on revealed by research." ScienceDaily. ScienceDaily, 10 July 2014. <www.sciencedaily.com/releases/2014/07/140710081212.htm>.
Biochemical Society. (2014, July 10). How key controller protein is switched on revealed by research. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2014/07/140710081212.htm
Biochemical Society. "How key controller protein is switched on revealed by research." ScienceDaily. www.sciencedaily.com/releases/2014/07/140710081212.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins